Gilead is known for its hepatitis C cures Sovaldi and Harvoni. But backlash to those drugs’ prices (among other problems) has contributed to the biotech giant’s 2016 slump. Gilead revenues fell nearly 7% to $30.4 billion in 2016 compared to the previous year. Some analysts have been urging the drug maker to make a major acquisition to shore up its experimental pipeline; but Gilead appears determined to invest in its own drug candidates by pumping money into R&D. And, in the meantime, it’s sitting on a massive bed of cash.
Looking for leads, investment insights, or competitive intelligence?
News about Gilead Sciences
They're more popular than ever, even though the political winds are against them.
FDA approves Novartis treatment that reengineers human cells to kill cancer
Kite Pharma stock rose 29% on the news.
AbbVie's victory is bad news for rival biotech giant Gilead.
If he pulls it off, he will make more than all of his peers combined.